Codeine in Urine: Detection Windows, Metabolites, and Test Interpretation

Codeine detection in urine depends on the interaction between your metabolism, the drug’s biochemical pathways, and the testing methods used to identify both the parent compound and its active metabolites.

Understanding these factors helps you anticipate detection windows, interpret test results accurately, and navigate employment or clinical testing situations with proper documentation and medical support.

Key Takeaways

• Detection window: Codeine typically appears in urine for 24 to 48 hours after a single dose in most adults; chronic or high-dose use can extend this to 72 hours or up to 7 days in some cases
• Metabolites matter: Urine tests detect both codeine and its primary metabolite morphine, plus conjugated forms like morphine-3-glucuronide and morphine-6-glucuronide
• Genetic variation affects results: CYP2D6 poor metabolizers show higher codeine-to-morphine ratios in urine, while ultrarapid metabolizers produce more morphine relative to parent drug
• Two-stage testing standard: Immunoassay screens are rapid (minutes to hours) but cross-reactive; confirmatory GC/MS or LC-MS/MS provides specific identification and typically takes 24 to 72 hours
• Workplace protections exist: Medical Review Officers (MROs) verify legitimate prescriptions before reporting positive results; several states enacted prescription privacy protections in 2024-2025 that shield employees with valid scripts from adverse actions
• Documentation prevents problems: Present your prescription bottle, clinician’s letter, and pharmacy records proactively when testing is scheduled

If you’re concerned about prescription drug misuse or navigating unexpected test results, medically supervised care can help you address both the clinical and practical challenges safely.

How Urine Testing for Codeine Works

Urine drug tests begin with an immunoassay screen that detects classes of opioids by antibody cross-reactivity rather than identifying a single molecule. A positive screen frequently triggers a confirmatory test by gas chromatography–mass spectrometry (GC/MS) or liquid chromatography–tandem mass spectrometry (LC-MS/MS), which identifies and quantifies specific molecules and metabolites.

Understanding the limits of each method helps set expectations about speed and certainty. Immunoassays deliver results within minutes to an hour for point-of-care devices but can produce false positives due to structural similarities with other compounds. Confirmatory testing is specific and generally required for forensic, legal, or employer-directed decisions.

The two-stage process exists because immunoassays are cost-effective for high-volume screening, while GC/MS and LC-MS/MS provide the accuracy needed when consequences are significant. If you’re facing testing as part of addiction treatment or employment requirements, knowing which test is being used helps you understand what the results actually measure.

Detection Windows: Typical Timing and Important Caveats

Codeine is usually detectable in urine for about 24 to 48 hours after a single dose in most adults. Higher or repeated dosing, reduced renal function, or slower metabolism can extend this window to 72 hours or more. Chronic daily use—particularly at high doses—can extend detection to 7 days in some documented cases, though this is less common.

Morphine, the primary active metabolite of codeine, may be detectable in a similar or slightly longer time frame depending on metabolism and dose. The persistence of morphine metabolites like morphine-3-glucuronide and morphine-6-glucuronide can influence how long a positive result appears even after codeine itself has cleared.

Body size, hydration, kidney function, frequency and amount of use, and metabolism speed all influence detection. These factors affect how a screen is interpreted and whether a confirmatory test is helpful for clarity. If you’re in medical detox or managing withdrawal, clinical teams use these timelines to monitor progress and ensure safety during the acute phase.

Codeine Detection Windows Across Different Test Types

Test Type	Detection Window	Typical Use Case	Notes
Urine	24-48 hours (single dose)<br>Up to 72 hours (repeated use)<br>Up to 7 days (chronic heavy use)	Standard workplace testing, clinical monitoring, probation/parole	Most common method; non-invasive; detects both codeine and morphine metabolites
Blood	Up to 24 hours	Acute intoxication assessment, post-accident testing, DUI investigation	Short window; invasive; confirms very recent use
Saliva	1-4 days	Roadside testing, recent use screening	Non-invasive; convenient; shorter window than urine
Hair	Up to 90 days (sometimes longer)	Long-term use history, forensic cases, child custody	Longest detection; shows historical patterns; cannot detect very recent use (2-3 week incorporation delay)

Understanding which test type is being used helps you interpret what the results actually measure and what timeframe they cover.

Main Metabolites and What Labs Look For

Codeine (parent drug) is excreted largely unchanged and also converted to metabolites. Morphine is the principal active metabolite produced via the liver enzyme CYP2D6.

Morphine-3-glucuronide and morphine-6-glucuronide are common conjugated metabolites that appear in urine. Norcodeine is another minor metabolite occasionally detected.

Immunoassays may detect codeine and morphine with varying sensitivity depending on the antibody design. Confirmatory GC/MS or LC-MS/MS can distinguish codeine from morphine and quantify concentrations for forensic or clinical interpretation. The ability to distinguish codeine from morphine matters when determining whether a positive result came from codeine use, morphine use, or poppy seed ingestion.

The codeine-to-morphine ratio in urine provides interpretive value. A high ratio of parent drug to metabolite suggests recent use or poor metabolizer status. A low ratio (more morphine relative to codeine) can indicate ultrarapid metabolism or, in some cases, direct morphine ingestion rather than codeine.

Labs use these ratios alongside cutoff thresholds to distinguish legitimate use from other sources.

Genetic Differences in CYP2D6 and Urine Test Results

Genetic variation in the CYP2D6 enzyme significantly affects how much codeine is converted to morphine. Poor metabolizers produce less morphine and may show proportionally higher parent-codeine relative to morphine in urine. Ultrarapid metabolizers produce more morphine and may have higher morphine-to-codeine ratios.

CYP2D6 Metabolizer Types and Test Result Patterns

Metabolizer Type	Population Prevalence	Codeine → Morphine Conversion	Typical Urine Pattern	Clinical Implications
Poor Metabolizer	~7-10% (varies by ethnicity)	Minimal conversion	High codeine, low morphine ratio	May be flagged for suspected morphine use when taking only codeine; reduced therapeutic effect from codeine
Intermediate Metabolizer	~10-15%	Reduced conversion	Moderately high codeine to morphine ratio	Slightly altered ratios but usually within normal interpretive range
Normal/Extensive Metabolizer	~70-80%	Standard conversion	Balanced codeine to morphine ratio	Standard therapeutic response and typical test interpretation
Ultrarapid Metabolizer	~1-5% (higher in certain populations)	Excessive conversion	Low codeine, high morphine ratio	May appear similar to direct morphine use; increased risk of side effects/toxicity from codeine

Genetic differences in CYP2D6 can alter the ratio of codeine to morphine detected but usually do not prevent codeine from being detected entirely. In clinical contexts where metabolizer status matters for safety or interpretation—such as pain management or dual diagnosis treatment planning—genetic testing and confirmatory urine assays give more precise information.

If you’re a known poor metabolizer or ultrarapid metabolizer, informing the testing program or Medical Review Officer ahead of time can prevent misinterpretation. Some individuals with atypical ratios have been flagged for suspected morphine use when they were taking only codeine as prescribed.

Documentation of metabolizer status, when available, resolves these discrepancies.

Poppy Seed Ingestion and “False Positives”

Poppy seeds may contain trace amounts of codeine and morphine. Consuming foods with poppy seeds can sometimes produce detectable urine levels, particularly with high-sensitivity assays or low laboratory cutoffs.

The likelihood of a positive result depends on the amount of poppy seeds eaten, the assay cutoff used, and timing relative to ingestion.

When an unexpected positive occurs, confirmatory testing and documentation about diet can help resolve whether poppy-seed ingestion is a plausible explanation. Most modern testing programs use higher cutoffs specifically to reduce poppy-seed false positives, but older protocols or more sensitive assays can still trigger results from dietary exposure.

If you consumed poppy seeds within 24 to 48 hours of testing and receive a positive result, request confirmatory testing and provide a dietary history to the Medical Review Officer. Labs can sometimes distinguish dietary morphine from pharmaceutical codeine or morphine by examining metabolite ratios, though this is not always definitive.

Immunoassay Cutoffs and Confirmatory Testing

Common workplace opiate immunoassay cutoffs have historically been 2000 ng/mL, but some programs and clinical labs use lower cutoffs such as 300 ng/mL for greater sensitivity. Cutoff policies vary by lab and testing program.

Lower cutoffs increase the chance of detecting low-level use but also increase the risk of false positives from dietary sources or cross-reactivity.

Immunoassay screens are rapid and suitable for initial detection but can cross-react with structurally similar substances. Confirmatory testing by GC/MS or LC-MS/MS is specific and generally required for forensic, legal, or employer-directed decisions.

Turnaround time for a typical point-of-care immunoassay is minutes to an hour. Confirmatory GC/MS or LC-MS/MS performed by a reference lab commonly takes 24 to 72 hours, though turnaround can be faster if the lab offers expedited processing or if testing is done in-house.

Standard turnaround for routine confirmatory testing is 48 hours. Expedited or stat testing can reduce this to 24 hours in facilities with in-house labs or priority processing agreements. Complex panels or additional metabolite analysis can extend results to 72 hours.

If you’re awaiting results that affect employment or treatment planning, ask the testing facility for their specific turnaround timeline.

How Other Medications and Treatments Affect Opiate Immunoassays

Medications used to treat opioid use disorder, such as methadone and buprenorphine, are not detected as “opiates” on standard natural-opiate immunoassays and do not typically cause a positive result for codeine or morphine. Methadone and buprenorphine require their own targeted assays if monitoring is intended.

Some non-opioid medications and chemical compounds can cause rare cross-reactivity or false positives on broad immunoassays. Quinolone antibiotics, rifampin, and certain other drugs have been reported to cause cross-reactivity in older assay designs, though modern tests have reduced this issue.

When clinical or occupational consequences are significant, confirmatory testing clarifies the finding.

Recreational codeine combinations—often called purple drank, lean, or sizzurp—typically mix codeine-containing cough syrup with promethazine, soda, or alcohol. While these combinations can affect absorption rates and metabolism, the codeine component generally follows similar urinary clearance patterns as pharmaceutical codeine alone.

Confirmatory GC/MS or LC-MS/MS testing can identify the specific compounds present and distinguish pharmaceutical codeine from recreational mixtures, though detection windows for the codeine itself remain largely consistent regardless of the formulation.

If you’re taking medications for opioid use disorder or other prescriptions and face drug testing, inform the testing program or Medical Review Officer in advance. Targeted assays for buprenorphine or methadone are separate panels and won’t interfere with codeine detection, but proactive disclosure prevents confusion during the review process.

Workplace Drug Testing Policy Shifts and Medical Review Officer Protections (2025-2026)

Recent state-level legislation and updated Medical Review Officer (MRO) protocols have strengthened protections for employees with legitimate prescriptions. California, New York, Illinois, and several other states enacted or expanded prescription privacy laws between 2024 and 2025, prohibiting employers from taking adverse actions solely based on lawful use of prescribed medications including opioids like codeine.

The MRO process has become more standardized across jurisdictions. When an immunoassay returns positive, the sample proceeds to confirmatory testing, and results are reviewed by a licensed Medical Review Officer before being reported to the employer.

The MRO contacts the individual to verify prescriptions, review medical records, and assess whether the result reflects legitimate use. Only unverified positives—those without a valid prescription or medical explanation—are reported as positive to the employer.

Pre-notification protocols now allow individuals to submit prescription documentation before testing in many programs, which expedites the MRO review process and reduces the risk of preliminary suspension or adverse action while results are pending. Some testing programs also recognize CYP2D6 genetic testing results when explaining atypical metabolite ratios, particularly in safety-sensitive positions where morphine detection from codeine use might otherwise raise concern.

Split-specimen testing has become a standard option for contested results. If you dispute a positive finding, the split specimen—a second aliquot from the same collection—can be sent to a different certified lab for independent analysis.

Observed versus unobserved collection protocols have also been refined to balance privacy with sample integrity in workplace settings.

These changes mean that having a valid prescription for codeine is less likely to result in job loss or adverse employment action than it was five years ago, provided you follow the disclosure process your employer’s testing program requires. If you work in a professional or first responder role where drug testing is routine, understanding these protections and documenting your prescriptions proactively is critical.

Documenting Legitimate Opioid Use for Employers or Testing Programs

If you have a prescribed codeine medicine and expect testing, practical documentation helps prevent misunderstanding. Present the original prescription bottle with pharmacy label showing your name, the medication, dosage, prescribing clinician, and fill date.

Provide a clinician’s note or treatment letter detailing the prescription and clinical need, particularly if the medication is for an ongoing condition.

Keep a printed record from your state prescription drug monitoring program (PDMP) if available. Many states allow patients to request their own PDMP report, which provides an official record of controlled substance prescriptions filled in your name.

Follow the testing program’s policy for pre-notification when a legitimate prescription exists—many programs allow you to submit documentation before the test or immediately after collection to streamline MRO review.

A confirmatory GC/MS or LC-MS/MS can also demonstrate the specific molecule present and help distinguish legitimate codeine use from other opioids or from non-prescribed use. If you’re in treatment or have concerns about misuse patterns, working with a clinician to document the therapeutic context protects both your employment and your health.

For individuals in specialty programs like veterans or professionals tracks, where privacy and employment continuity are particularly important, proactive documentation and MRO communication are standard parts of navigating workplace requirements during or after treatment.

Can Passive Exposure Cause a Positive Urine Test?

Passive exposure from being near someone using opioids is extremely unlikely to produce a positive urine test under normal circumstances. For inhalational or environmental exposure to reach the thresholds detectable in urine, exposure would have to be unusually intense and prolonged.

Routine close contact with someone using opioids is not a common cause of a positive urine result.

If someone believes a positive result came from passive exposure, confirmatory testing and documentation of the exposure circumstances can help evaluate that claim. The concentration of drug detected, the presence or absence of specific metabolites, and the individual’s own medical and prescription history all inform whether passive exposure is plausible.

In nearly all documented cases, passive exposure does not produce detectable levels.

Interpreting Results in a Clinical or Employment Context

Positive immunoassay screens should be treated as preliminary. Confirmatory analysis identifies the specific analytes and their concentrations.

Clinical context—recent prescriptions, timing of dosing, renal function, and possible dietary exposures—matters when interpreting results.

When safety concerns or treatment decisions are at stake, a thorough review that includes confirmatory testing and clinical documentation is the responsible approach. If you’re in withdrawal management or residential care, clinical teams use urine testing to monitor adherence, detect undisclosed use, and track metabolic clearance during stabilization.

In these settings, testing is a clinical tool, not a punitive measure.

For employment testing, the MRO review process is designed to distinguish legitimate medical use from misuse. If you receive notice of a positive result, respond promptly with documentation and communicate openly with the MRO.

Most contested results are resolved at this stage without escalating to the employer if the prescription is valid and properly documented.

Care, Support, and Next Steps for People Navigating Positive Tests or Opioid Concerns

People navigating an unexpected positive urine test or questions about opioid use often need clinical guidance and compassionate support. If withdrawal, safety concerns, or dependence are present, medically supervised detox and residential care provide clinical oversight, one-on-one therapy as part of structured programs, and 24/7 nursing support for safe stabilization.

Journey Hillside Tarzana offers private, six-bed residential care with an in-person medical director and specialty tracks for veterans, first responders, and professionals to support individualized treatment planning and next steps.

Call (877) 414-1024 to speak confidentially with our admissions team about clinical next steps and options for safe stabilization.

Frequently Asked Questions About Codeine in Urine

Should I tell my clinician about a prescribed codeine medicine before a urine opioid test?

Yes. Sharing prescribed medications with the clinician or testing administrator helps ensure accurate interpretation and can prevent unnecessary concern. Provide the prescription bottle or a clinician’s note when feasible. If the test is for employment or legal reasons, follow the program’s policy for disclosing prescription medications before testing.

Will a single therapeutic dose of codeine always produce a positive urine result?

No. A single therapeutic dose may or may not trigger a positive result depending on the dose, the time between dosing and testing, your metabolism, kidney function, and the immunoassay cutoff used. Low-dose or well-timed dosing can fall below certain laboratory cutoffs, while higher doses or sensitive cutoffs are more likely to be positive.

Are commercially available home urine tests reliable for detecting codeine?

Home urine tests can detect opiates in many cases but vary in sensitivity and specificity. They are useful for preliminary screening but can produce false negatives or false positives. For any result with significant consequences, a laboratory-based immunoassay followed by GC/MS or LC-MS/MS confirmatory testing is more reliable and accepted by employers and legal systems.

Can passive exposure (e.g., being near someone using opioids) cause a positive urine test?

Passive exposure under ordinary circumstances is very unlikely to yield a positive urine result. Detectable levels typically require direct ingestion or concentrated exposure. If someone believes a positive result came from passive exposure, confirmatory testing and documentation of the exposure circumstances can help evaluate that claim.

How long do confirmatory GC/MS or LC-MS/MS results typically take compared with an immunoassay screen?

Immunoassay screens give rapid results, often within minutes to an hour for point-of-care or clinic devices. Confirmatory GC/MS or LC-MS/MS testing performed by a reference laboratory usually takes 24 to 72 hours, though expedited processing may be available in some situations. Standard turnaround is 48 hours for routine confirmatory work.

Can medications for opioid use disorder (buprenorphine, methadone) affect opiate immunoassays?

Typical natural-opiate immunoassays for codeine and morphine do not detect methadone or buprenorphine. These medications require targeted assays if monitoring is intended. If you are taking medication for opioid use disorder and testing is required, inform the testing program so the appropriate panels are ordered.

How should I document legitimate opioid use to explain a positive result to an employer or testing program?

Keep and present a current pharmacy label on the medication bottle, a clinician’s letter explaining the prescription, and PDMP records if available. Notify the testing program per their instructions and request confirmatory GC/MS or LC-MS/MS if a preliminary screen is positive and clarification is needed.

Do genetic differences in CYP2D6 significantly change how codeine shows up on a urine test?

Genetic variability in CYP2D6 affects conversion of codeine to morphine, altering the ratio of parent drug to metabolite seen in urine. Poor metabolizers tend to have less morphine, while ultrarapid metabolizers may have higher morphine levels. These differences influence interpretation but rarely make codeine undetectable entirely; confirmatory tests provide the most definitive information.

If You or a Loved One Needs Help Interpreting a Test Result or Safely Managing Opioid Use

People navigating positive drug tests, medication questions, or withdrawal deserve compassionate, medically supervised care. If safety, detox, or treatment may be needed, our team at Journey Hillside Tarzana provides 24/7 nursing support, an in-person medical director, and private, six-bed residential programs with individualized clinical oversight.

Speak confidentially with our admissions team to understand clinical next steps and options for safe stabilization.

Call (877) 414-1024 or contact us online to learn more about how we can support you.